Bisphosphonates: Mechanism of Action and Role in Clinical Practice
作者： Matthew T. Drake , Bart L. Clarke , Sundeep Khosla
DOI: 10.4065/83.9.1032
关键词:
摘要: Bisphosphonates are primary agents in the current pharmacological arsenal against osteoclast-mediated bone loss due to osteoporosis, Paget disease of bone, malignancies metastatic multiple myeloma, and hypercalcemia malignancy. In addition currently approved uses, bisphosphonates commonly prescribed for prevention treatment a variety other skeletal conditions, such as low density osteogenesis imperfecta. However, recent recognition that bisphosphonate use is associated with pathologic conditions including osteonecrosis jaw has sharpened level scrutiny widespread therapy. Using key words clinical practice PubMed literature search from January 1, 1998, May 2008, we review understanding mechanisms by which exert their effects on osteoclasts, discuss role practice, highlight some areas concern use.
mayoclinicproceedings.org
elsevier.com
lievers.net参考文章(141)
Abdullah Bereket, Tulay Guran, Teoman Akcay, Serap Turan, Alendronate treatment in children with osteogenesis imperfecta Indian Pediatrics. ,vol. 45, pp. 105- 109 ,(2008)
P Garnero, N Buchs, J Zekri, R Rizzoli, R E Coleman, P D Delmas, Markers of bone turnover for the management of patients with bone metastases from prostate cancer British Journal of Cancer. ,vol. 82, pp. 858- 864 ,(2000) , 10.1054/BJOC.1999.1012
Antonella Barone, Andrea Giusti, Giulio Pioli, Giuseppe Girasole, Monica Razzano, Monica Pizzonia, Ernesto Palummeri, Gerolamo Bianchi, Secondary Hyperparathyroidism Due to Hypovitaminosis D Affects Bone Mineral Density Response to Alendronate in Elderly Women with Osteoporosis: A Randomized Controlled Trial Journal of the American Geriatrics Society. ,vol. 55, pp. 752- 757 ,(2007) , 10.1111/J.1532-5415.2007.01161.X
James R. Berenson, Lee S. Rosen, Anthony Howell, Lester Porter, Robert E. Coleman, Walter Morley, Robert Dreicer, Steven A. Kuross, Allan Lipton, John J. Seaman, Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: A double-blind, randomized dose-response study Cancer. ,vol. 91, pp. 1191- 1200 ,(2001) , 10.1002/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0
Leanne Ward, Andrea Tricco, Phuc-Nhi Phuong, Ann Cranney, Nick Barrowman, Isabelle Gaboury, Frank Rauch, Peter Tugwell, David Moher, Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database of Systematic Reviews. ,(2007) , 10.1002/14651858.CD005324.PUB2
Kazuhiro Ishizaka, Tatsuya Machida, Shuichiro Kobayashi, Naoko Kanbe, Satoshi Kitahara, Ken-Ichiro Yoshida, Preventive effect of risedronate on bone loss in men receiving androgen‐deprivation therapy for prostate cancer International Journal of Urology. ,vol. 14, pp. 1071- 1075 ,(2007) , 10.1111/J.1442-2042.2007.01911.X
Diane K. Wysowski, Jennie T. Chang, Alendronate and Risedronate: Reports of Severe Bone, Joint, and Muscle Pain JAMA Internal Medicine. ,vol. 165, pp. 346- 347 ,(2005) , 10.1001/ARCHINTE.165.3.346-B
Writing Group for the Women's Health Initiative Investigators, Writing Group for the Women's Health Initiative Investigators, None, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial JAMA. ,vol. 288, pp. 321- 333 ,(2002) , 10.1001/JAMA.288.3.321
MN Khan, Aliya A Khan, Cancer treatment-related bone loss: a review and synthesis of the literature. Current Oncology. ,vol. 15, ,(2008) , 10.3747/CO.2008.174
Markus Cybulla, Günter Kirste, Wolfgang Grotz, Markus Uhl, Manfred Olschewski, Achim Reichelt, Christoph Strey, Daria Poeschel, Karl-Georg Petersen, Christian Nagel, Lars Christian Rump, Effect of Ibandronate on Bone Loss and Renal Function after Kidney Transplantation Journal of The American Society of Nephrology. ,vol. 12, pp. 1530- 1537 ,(2001) , 10.1681/ASN.V1271530